This inventor holds 0 USPTO granted patents, plus 6 CIPO patents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Title: Tien-Lan Hsieh: Innovator in Central Nervous System Treatments
Introduction
Tien-Lan Hsieh is a notable inventor based in China, recognized for his contributions to the field of pharmaceutical compositions aimed at treating central nervous system disorders. His innovative work focuses on the development of compositions that utilize unique compounds for therapeutic purposes.
Latest Patents
Hsieh's latest patents include "Compositions Containing Benzoate Compound And Tannic Acid For Treating Central Nervous System Disorders." This patent describes pharmaceutical and nutraceutical compositions that comprise a benzoate compound and an excipient, specifically tannic acid, which are used for treating various central nervous system disorders. Another significant patent is "Co-Crystals Of Lithium Benzoate And Uses Thereof." This disclosure provides co-crystals of a lithium benzoate compound and a co-former compound, along with methods for preparing these co-crystals and their applications in treating neuropsychiatric disorders such as schizophrenia and bipolar disorders.
Career Highlights
Hsieh is currently associated with Syneurx International Corp., where he continues to advance his research and development efforts in the pharmaceutical industry. His work is pivotal in addressing critical health issues related to mental health and neurodegenerative diseases.
Collaborations
Hsieh collaborates with Ching-Cheng Wang, who is also involved in research and development within the same field. Their partnership enhances the potential for innovative solutions in treating complex disorders.
Conclusion
Tien-Lan Hsieh's contributions to the field of central nervous system treatments through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic options that can significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile